Janin N, Meugnier H, Desnottes J F, Woehrle R, Fleurette J
Laboratoire de Bactériologie, Faculté de Médecine Alexis-Carrel, Antony, France.
Antimicrob Agents Chemother. 1987 Nov;31(11):1665-8. doi: 10.1128/AAC.31.11.1665.
Pefloxacin, a new fluoroquinolone, was given to 10 volunteers in single 400-mg oral doses repeated at 12-h intervals during 7 days. Serum, saliva, and feces samples were collected before and at appropriate intervals after the initiation of treatment. Drug concentrations were determined by bioassay. Qualitative and quantitative analyses of the saliva and fecal floras were performed. Mean concentrations in saliva (3.46 micrograms/ml on day 1 and 7.54 micrograms/ml on day 7) were closely related to levels in serum. High concentrations of pefloxacin were found in the feces (645 micrograms/g on day 8). No modification of oral flora was observed. In the fecal flora, members of the family Enterobacteriaceae were eliminated between days 2 and 8. The alterations in streptococci and anaerobic flora were not significant; Bacteroides fragilis was more resistant to pefloxacin after treatment. Clostridium difficile was not detected, and there was no overgrowth by yeasts. No side effects were observed.
培氟沙星是一种新型氟喹诺酮类药物,对10名志愿者进行了试验,单次口服400毫克剂量,每12小时重复给药一次,共持续7天。在治疗开始前及治疗开始后的适当时间间隔采集血清、唾液和粪便样本。通过生物测定法测定药物浓度。对唾液和粪便菌群进行定性和定量分析。唾液中的平均浓度(第1天为3.46微克/毫升,第7天为7.54微克/毫升)与血清中的水平密切相关。粪便中发现高浓度的培氟沙星(第8天为645微克/克)。未观察到口腔菌群的改变。在粪便菌群中,肠杆菌科成员在第2天至第8天之间被清除。链球菌和厌氧菌群的变化不显著;治疗后脆弱拟杆菌对培氟沙星更具耐药性。未检测到艰难梭菌,也没有酵母菌过度生长。未观察到副作用。